John Aducci, Marlea Ahrend, Stella Ahrend, Emma Arenas, Skyler Attebery, Lauren Baber, Cooper Barnes, Kaydence Beale, Jake Blanck, Naomi Cavener, Cullen Christian ...

Kaytlin Alm, Kennadee Bickerstaff, Brooklyn Black, Jessi Bolin, Jordan Brown, Zoey Brown, Kaison Callahan, Emanuel Camacho, Keith Cook, Kennedi Cutler, Gabby Diaz ...

Lilly Gannawya scored eight points, had seven rebounds, three assists and three steals. In the junior varsity contest, St. Anthony won 42-24. Aubrey Denning led with 13 while Jackie Vonderheide and ...

Altamont held a 14-11 opening quarter lead as Ella Nelson, Libby Reardon, Reagan Kuenstler and Kylie Osteen hit a three-pointer each. Osteen added two free throws for five points. Neoga's Brynn ...

Lily Allen is sharing details surrounding a recent visit to a treatment center. The singer discussed the visit on the latest episode of her BBC podcast “Miss Me?” with her cohost Miquita ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Boris Becker's ex-wife Lilly has won the German version of I'm A Celebrity... Get Me Out Of Here! after stealing the hearts of the nation. The former Wimbledon tennis star, 57, has endured a ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...

Eli Lilly LLY-N on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...